DDIAS, DNA damage-induced apoptosis suppressor, is a potential therapeutic target in cancer

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• DNA damage-induced apoptosis suppressor (DDIAS) is increasingly recognized as an oncogenic protein.
• High expression of DDIAS is observed in various cancers, including colorectal, lung, breast, and hepatocellular carcinoma (HCC).

Purpose of the Study:

• To review the multifaceted roles of DDIAS in human cancer biology.
• To explore DDIAS and its regulatory proteins as potential therapeutic targets.
• To discuss the development and future prospects of DDIAS inhibitors.

Main Methods:

• Literature review of recent studies on DDIAS function and regulation in cancer.
• Analysis of DDIAS involvement in tumorigenesis, metastasis, DNA repair, and drug resistance.
• Examination of DDIAS binding partners and their roles in different cancer types.

Main Results:

• DDIAS is implicated in key cancer processes such as tumor initiation, spread, DNA maintenance, and treatment resistance.
• DDIAS exhibits diverse functions mediated by various binding partners across different human cancers.
• The protein's oncogenic nature highlights its significance in cancer progression.

Conclusions:

• DDIAS represents a significant and novel therapeutic target for various human cancers.
• Understanding DDIAS regulatory proteins is crucial for developing effective cancer therapies.
• Further research into DDIAS inhibitors holds promise for future cancer treatment strategies.